By Pathogen
By Disease
By Drug Class
By Mechanism of Action
By Distribution Channel
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibiotic Resistance Market Snapshot
Chapter 4. Global Antibiotic Resistance Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Antibiotic Resistance Market Industry Trends
4.10. Global Antibiotic Resistance Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Antibiotic Resistance Market Segmentation 1: By Pathogen, Estimates & Trend Analysis
5.1. Market Share by Pathogen, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Pathogen:
5.2.1. E. coli
5.2.2. K. pneumoniae
5.2.3. P. aeruginosa
5.2.4. S. aureus
5.2.5. A. baumannii
5.2.6. S. pneumoniae
5.2.7. H. influenzae
5.2.8. C. difficile
5.2.9. E. faecium
Chapter 6. Antibiotic Resistance Market Segmentation 2: By Disease, Estimates & Trend Analysis
6.1. Market Share by Disease, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Disease:
6.2.1. cUTI (Complicated Urinary Tract Infections)
6.2.2. CDI (Clostridioides difficile Infection)
6.2.3. ABSSSI (Acute bacterial skin and skin structure infections)
6.2.4. HABP (Hospital-acquired bacterial pneumonia)
6.2.5. CABP (Community-acquired pneumonia)
6.2.6. cIAI (Complicated intra-abdominal infection)
6.2.7. BSI (Bloodstream infection)
Chapter 7. Antibiotic Resistance Market Segmentation 3: By Drug Class, Estimates & Trend Analysis
7.1. Market Share by Drug Class, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Class:
7.2.1. Oxazolidinones
7.2.2. Lipoglycopeptides
7.2.3. Tetracyclines
7.2.4. Combination therapies
7.2.5. Cephalosporins
7.2.6. Others
Chapter 8. Offline Antibiotic Resistance Market Segmentation 4: By Mechanism of Action, Estimates & Trend Analysis
8.1. Market Share by Mechanism of Action, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Mechanism of Action:
8.2.1. Protein Synthesis Inhibitors
8.2.2. Cell Wall Synthesis Inhibitors
8.2.3. RNA Synthesis Inhibitors
8.2.4. DNA Synthesis Inhibitors
8.2.5. Others
Chapter 9. Antibiotic Resistance Market Segmentation 5: By Distribution Channel, Estimates & Trend Analysis
9.1. Market Share by Distribution Channel, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
Chapter 10. Antibiotic Resistance Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Antibiotic Resistance Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Pathogen, 2021-2034
10.2.3. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
10.2.4. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2021-2034
10.2.5. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action, 2021-2034
10.2.6. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.3. Europe
10.3.1. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Pathogen, 2021-2034
10.3.3. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
10.3.4. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2021-2034
10.3.5. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action, 2021-2034
10.3.6. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Pathogen, 2021-2034
10.4.3. Asia Pacific Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
10.4.4. Asia Pacific Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts Mechanism of Action, 2021-2034
10.4.5. Asia Pacific Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.5. Latin America
10.5.1. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Pathogen, 2021-2034
10.5.3. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
10.5.4. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2021-2034
10.5.5. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action, 2021-2034
10.5.6. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Pathogen, 2021-2034
10.6.3. Middle East & Africa Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
10.6.4. Middle East & Africa Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2021-2034
10.6.5. Middle East & Africa Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action, 2021-2034
10.6.6. Middle East & Africa Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. The Medicines Company
11.2.1.1. Business Overview
11.2.1.2. Key Pathogen/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Melinta Therapeutics
11.2.3. Arsanis
11.2.4. Phage Technologies S.A
11.2.5. Westway Health
11.2.6. Tetraphase Pharmaceuticals
11.2.7. BioVersys GmbH
11.2.8. Nabriva Therapeutics.
11.2.9. Macrolide Pharmaceuticals
11.2.10. Nemesis Bioscience
11.2.11. C3J Therapeutics, Inc
11.2.12. EpiBiome
11.2.13. discuva
11.2.14. SmartPhage
11.2.15. AmpliPhi Biosciences
11.2.16. Pherecydes Pharma
11.2.17. Micreos
11.2.18. Procarta Biosystems
11.2.19. Lumavita
11.2.20. Madam Therapeutics
11.2.21. Priaxon
11.2.22. Biolytx Pharmaceuticals
11.2.23. AntibioTx
11.2.24. Xellia Pharmaceuticals
11.2.25. Paratek Pharmaceuticals
11.2.26. Synereca Pharmaceuticals
11.2.27. Allecra Therapeutics
11.2.28. Fixed Phage
11.2.29. Enanta Pharmaceuticals, Inc
11.2.30. Demuris
11.2.31. Prommune
11.2.32. Biosergen
11.2.33. Innovation Pharmaceuticals
11.2.34. Aviragen Therapeutics
11.2.35. Achillion Pharmaceuticals
11.2.36. ImmunNovative Developments, S.L.
11.2.37. Achaogen, Inc.
11.2.38. SelectX Pharmaceuticals, Inc.
11.2.39. TaiGen Biotechnology Co., Ltd
11.2.40. Theravance Biopharma
11.2.41. Abbvie
11.2.42. KYORIN Pharmaceutical Co., Ltd.
11.2.43. Iterum Therapeutics Limited
11.2.44. Forge Therapeutics
11.2.45. Alopexx Vaccine LLC
11.2.46. Integrated Biotherapeutics
11.2.47. Hennepin Life Sciences
11.2.48. Fedora Pharmaceuticals Inc
11.2.49. Contrafect Corporation
11.2.50. Basilea Pharmaceutica Ltd.
11.2.51. AiCuris
11.2.52. RedHill Biopharma
11.2.53. Redx Pharma Plc/ Redx Anti Infectives Ltd.
11.2.54. ABAC Therapeutics
11.2.55. Alaxia SAS
11.2.56. Antabio S.A.S
11.2.57. Auspherix Ltd
11.2.58. BioFilm Pharma
11.2.59. Centauri Therapeutics Ltd
11.2.60. Combioxin SA
11.2.61. Da Volterra
11.2.62. Debiopharm International SA
11.2.63. Deinobiotics/Deinove
11.2.64. Destiny Pharma plc
11.2.65. Eligo Bioscience
11.2.66. Helperby Therapeutics Ltd
11.2.67. Karveel Pharmaceuticals
11.2.68. MaaT Pharma
11.2.69. Motif BioSciences, Inc / Motif Bio PLC
11.2.70. Mutabilis SAS
11.2.71. Neem Biotech Ltd
11.2.72. Northern Antibiotics Oy (Ltd)
11.2.73. Nosopharm
11.2.74. NovaBiotics Ltd
11.2.75. Phico Therapeutics Ltd
11.2.76. Polyphor Ltd
11.2.77. QureTech Bio AB
11.2.78. SetLance Srl
11.2.79. Ultupharma AB
11.2.80. Vaxdyn
11.2.81. Vibiosphen
11.2.82. Bioaster
11.2.83. Vivexia
11.2.84. KBP Biosciences
11.2.85. Absynth Biologics
11.2.86. Spero Therapeutics
11.2.87. Merck
11.2.88. Symphogen
11.2.89. Warp Drive Bio
11.2.90. Johnson & Johnson (Janssen)
11.2.91. Pfizer
11.2.92. Allergan
11.2.93. Novartis
11.2.94. AstraZeneca
11.2.95. Cipla
11.2.96. DSM Sinochem Pharmaceuticals
11.2.97. Wockhardt Ltd.
11.2.98. VenatoRx Pharmaceuticals
11.2.99. MicuRx
11.2.100. Entasis Therapeutics
11.2.101. Merlion Pharmaceuticals
11.2.102. Aridis Pharmaceuticals Inc.
11.2.103. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.